| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 5.62 | -0.11 (-1.92%) | 5.50 - 8.25 | 1.7 thousand (Below Avg) |
Market data as of 11:01AM 05/23/13. Quotes are delayed by at least 15 min.
| Open | 5.70 |
|---|---|
| Previous Close | 5.73 |
| Day's Range | 5.59 - 5.97 |
| Market Cap | 135.9M |
| Avg Volume (10 Day) | 16.3K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Neutral |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
KaloBios Reports First Quarter 2013 Financial Results
PR Newswire - Tuesday 05/14/2013 4:00 PM ET
KaloBios to Present at Credit Suisse Antibody Conference
PR Newswire - Wednesday 05/08/2013 4:00 PM ET
Sofinnova Ventures Announces Team Expansion and Promotion
PR Newswire - Thursday 05/02/2013 6:00 AM ET
KaloBios to Present at Needham Healthcare Conference
PR Newswire - Wednesday 04/24/2013 4:00 PM ET
U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios' Novel Biologic Candidate for Pseudomonas aeruginosa
PR Newswire - Tuesday 04/23/2013 8:00 AM ET
| KBIO | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|---|---|
| Alimera Sciences Inc | 4.40 | -0.54% |
| Horizon Pharma Inc | 2.38 | -0.42% |
| Zogenix Inc | 1.55 | +2.65% |
| Ampio Pharmaceuticals Inc | 5.01 | +6.82% |
| Rockwell Medical Inc | 3.95 | +1.80% |
Data is delayed by at least 15 min.